| Ticker |
PACB
|
| CIK | 0001299130 |
| SIC | 3826 |
| Sector | Manufacturing |
| Industry Category | Measuring And Control Equipment |
| Industry Group | Lab Analytical Instruments |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key MetricsBeyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025. Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI ModelsThe most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based toolsMENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic variation which characterizes simple and complex variation. These improved benchmarks were used to retrai 3 Reasons to Avoid PACB and 1 Stock to Buy InsteadPacBio currently trades at $1.47 per share and has shown little upside over the past six months, posting a small loss of 4.5%. The stock also fell short of the S&P 500’s 5.4% gain during that period. Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key InsightsPacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close. PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To KnowA number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. |
